Liverpool ChiroChem
Liverpool ChiroChem manufactures and supplies automated chiral chemistry building blocks for pharmaceutical and biotechnology research. Founded in 2014 in Liverpool, UK, the company was acquired by XtalPi in June 2025 to accelerate drug and materials discovery across US, Europe, and Asia.
- Company typePrivate
- Founded2014
- HeadquartersLiverpool, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Liverpool ChiroChem does
Liverpool ChiroChem (LCC) is a UK-based specialist chemistry company founded in 2014, headquartered in Liverpool, that manufactures and supplies chiral building blocks used in pharmaceutical research and biotechnology. Its core capability is automated chiral chemistry — the production of stereochemically defined molecular building blocks — positioned as a leader in this niche with applications spanning drug discovery and materials science. The company's customers are research-oriented pharmaceutical and biotechnology organizations, and following its June 2025 acquisition by XtalPi, its reach explicitly extends across the US, Europe, and Asia.
LCC is a small, focused operation with 11–50 employees, led by co-founder and CEO Paul Colbon and co-founder and CSO Jiwu Ruan, supported by chairman Stephen Parker, CFO Philip Tottey, and business development manager Samuel Kirkwood. Between 2018 and 2021 the company raised approximately $7.46M across four funding rounds from a consistent UK investor syndicate led by Praetura Ventures, Deepbridge Capital, Northern Powerhouse Investment Fund, and NPIF Maven Equity Finance — a funding cadence consistent with a capital-efficient research-services firm rather than a heavily capitalized platform play.
On June 13, 2025, XtalPi announced its strategic acquisition of LCC, combining LCC's automated chiral chemistry platform with XtalPi's AI-driven drug discovery capabilities. The deal is positioned to accelerate chemical space exploration and compound discovery for pharmaceutical and materials applications, while giving LCC access to XtalPi's tri-continental commercial infrastructure. Pre-acquisition revenue and pricing are not publicly disclosed; the business model is consistent with B2B supply of specialist chemistry building blocks to pharma/biotech R&D groups.
Liverpool ChiroChem firmographics
Firmographics- Name
- Liverpool ChiroChem
- Website
- https://liverpoolchirochem.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Liverpool ChiroChem manufactures and supplies automated chiral chemistry building blocks for pharmaceutical and biotechnology research. Founded in 2014 in Liverpool, UK, the company was acquired by XtalPi in June 2025 to accelerate drug and materials discovery across US, Europe, and Asia.
- Ownership category
- akta.pro rank
Liverpool ChiroChem industry classification
Industry- Product category
- Specialty Chemical Manufacturing
- NAICS
- Medicinal and Botanical Manufacturing (325411), Chemical Manufacturing (325), Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing (325194)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)
- akta.pro primary industry
- Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)
Keywords
Where Liverpool ChiroChem is headquartered
LocationHeadquarters
- HQ city
- Liverpool
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Liverpool ChiroChem business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Liverpool ChiroChem product offering
Product offeringCore offering
Liverpool ChiroChem manufactures and supplies specialist chiral building blocks used in pharmaceutical research and biotechnology. Leveraging automated chiral chemistry, the company accelerates the discovery of novel compounds for drug development and materials science applications across the US, Europe, and Asia markets.
Product overview
Liverpool ChiroChem (LCC) operates as a standalone automated chiral chemistry service provider. The company was acquired by XtalPi in June 2025 to enhance chemical space exploration capabilities. Based on available sources, limited product portfolio details are provided; the company is identified as a leader in automated chiral chemistry serving pharmaceutical and materials science sectors across US, Europe, and Asia markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Liverpool ChiroChem (LCC) Chiral Building Blocks
Companies that use Liverpool ChiroChem
Customer profileIdeal customer profiles1 record
Liverpool ChiroChem technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Liverpool ChiroChem partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- XtalPicoreXtalPi announced strategic acquisition of Liverpool ChiroChem (LCC). The merger aims to unlock unprecedented power in chemical space exploration by combining LCC's automated chiral chemistry capabilities with XtalPi's existing platforms. This acquisition enhances pharmaceutical and materials compound discovery across US, Europe, and Asia markets.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
Liverpool ChiroChem competitors and assessment
Company assessmentDirect peers
- Combi-Blocks: Specialty chemistry supplier of screening compounds and building blocks, including chiral and heterocyclic scaffolds, serving pharmaceutical R&D customers globally — direct competitor to LCC in chiral building blocks.
- Enamine: Ukraine-based supplier of building blocks, screening libraries, and custom synthesis services for pharma and agrochemical R&D, with a large catalogue overlapping LCC's chiral and complex small-molecule offerings.
- Bide Pharmatech: China-based supplier of building blocks, intermediates, and chiral compounds for drug discovery, with comparable product breadth and pricing competition to LCC in pharma R&D catalogues.
- Strem Chemicals: Specialty chemicals manufacturer and distributor focused on catalysts, ligands, and organometallics — comparable in serving pharma and materials R&D with niche chiral reagents.
- Asymchem: China-based CDMO with strong capabilities in chiral synthesis, asymmetric catalysis, and complex API development — directly comparable in chiral chemistry services for pharma customers.
Broad incumbents
- Sigma-Aldrich (Merck KGaA): Global life science and specialty chemicals incumbent with a massive catalogue including chiral building blocks and reagents, supplying pharma and academic labs — broader portfolio but overlapping in chiral chemistry.
- WuXi AppTec: Global CRO/CDMO offering discovery, preclinical, and manufacturing services with substantial chiral chemistry capability — much larger scale, overlapping in pharma building blocks and intermediates.
- ChemPartner: China-based CRO providing chemistry services including custom synthesis, chiral chemistry, and medicinal chemistry for global pharma — adjacent competitor in discovery chemistry.
- Aurigene Pharmaceutical Services: CRO/CDMO offering custom synthesis, chiral chemistry, and process development for pharma — comparable service offering but with broader drug discovery portfolio than LCC.
Regional players
- BioAscent: Scotland-based CRO offering medicinal chemistry and drug discovery services to European pharma/biotech — comparable in chemistry services but primarily serves European clients.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Liverpool ChiroChem social profiles
Digital presenceLiverpool ChiroChem financial estimates
Financial estimateRevenue estimate
Valuation estimate
Liverpool ChiroChem leadership team
Management profileNumber of profiles
Profiles6 records
Liverpool ChiroChem funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Liverpool ChiroChem M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Liverpool ChiroChem
What does Liverpool ChiroChem do?
Liverpool ChiroChem manufactures and supplies specialist chiral building blocks used in pharmaceutical research and biotechnology. Leveraging automated chiral chemistry, the company accelerates the discovery of novel compounds for drug development and materials science applications across the US, Europe, and Asia markets.
Is Liverpool ChiroChem a public or private company?
Liverpool ChiroChem is a private company. It is classified as corporate owned and is currently acquired.
When was Liverpool ChiroChem founded?
Liverpool ChiroChem was founded in 2014. It employs 11 to 50 people.
Where is Liverpool ChiroChem based?
Liverpool ChiroChem is headquartered in Liverpool, United Kingdom, in the Europe region.
Who are Liverpool ChiroChem's main competitors?
Direct peers on record are Combi-Blocks, Enamine, Bide Pharmatech, Strem Chemicals and Asymchem. Broad incumbents are Sigma-Aldrich (Merck KGaA), WuXi AppTec, ChemPartner and Aurigene Pharmaceutical Services. BioAscent is listed as a regional player.
Does Liverpool ChiroChem have an API?
No public API is recorded for Liverpool ChiroChem.
What industry is Liverpool ChiroChem in?
Liverpool ChiroChem's product category is Specialty Chemical Manufacturing. Its primary akta.pro industry code is HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 325411 and its SIC code is 2833.